Airway inflammation induced after allergic poly-sensitization can be prevented by mucosal but not by systemic administration of poly-peptides

Clinical and Experimental Allergy

Volumn 38, Issue 7, 2008, Pages 1192-1202

  Hufnagl, K ^a   Focke, M ^a   Gruber, F ^b   Hufnagl, P ^c   Loupal, G ^d   Ner, O Schei ^a   Wiedermann, U ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

^c Roche Diagnostics GmbH   (Austria)

^d UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

Airway inflammation; Foxp3; Hybrid; IL 10; Mucosal tolerance; Poly Sensitization; Polypeptides; Polyvalent vaccine; Type i allergy

Indexed keywords

ALLERGEN; BET V 1 ALLERGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EOTAXIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; PHL P 1 ALLERGEN; PHL P 5 ALLERGEN; POLLEN EXTRACT; POLYPEPTIDE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VACCINE; CYTOKINE; IMMUNOGLOBULIN G; PEPTIDE;

ALLERGIC REACTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASOPHIL DEGRANULATION; BIRCH; CD3+ T LYMPHOCYTE; CELL CULTURE; CELL INFILTRATION; CONTROLLED STUDY; EOSINOPHIL; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; LUNG ALVEOLUS CELL; LUNG LAVAGE; LUNG PARENCHYMA; MOUSE; NONHUMAN; PHLEUM PRATENSE; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; SPLEEN CELL; TH1 CELL; TH2 CELL; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BASOPHIL; BIOSYNTHESIS; BLOOD; DEGRANULATION; DESENSITIZATION; HYPERSENSITIVITY; IMMUNOLOGY; INFLAMMATION; LUNG; METABOLISM; NOSE MUCOSA; PATHOLOGY; POLLEN; RAT; RESPIRATORY SYSTEM; T LYMPHOCYTE SUBPOPULATION;

ALLERGENS; ANIMALS; BASOPHILS; CELL DEGRANULATION; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; EOSINOPHILS; FEMALE; HYPERSENSITIVITY; IMMUNOGLOBULIN G; INFLAMMATION; LUNG; MICE; MICE, INBRED BALB C; NASAL MUCOSA; PEPTIDES; POLLEN; RATS; RESPIRATORY SYSTEM; T-LYMPHOCYTE SUBSETS;

EID: 54449093890     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2008.02992.x     Document Type: Article

References (34)

1. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Mailing HJ, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy 2006; 61(Suppl. 82):1-20.
2. Jutel M, Akdis M, Blaser K, Akdis CA. Mechanisms of allergen specific immunotherapy - T-cell tolerance and more. Allergy 2006; 61:796-807.
3. Valovirta E, Passalacqua G, Canonica WG. Non-injection routes for immunotherapy of allergic diseases. Clin Allergy Immunol 2004; 18:607-23.
4. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61:151-65.
5. Wiedermann U. Prophylaxis and therapy of allergy by mucosal tolerance induction with recombinant allergens or allergen constructs. CurrDrug Targets Inflamm Allergy 2005; 4:577-83.
6. Larche M. Peptide therapy for allergic diseases: basic mechanisms and new clinical approaches. Pharmacol Ther 2005; 108:353-61.
7. Wiedermann U, Herz U, Baier K et al. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice. Int Arch Allergy Immunol 2001; 126:68-77.
8. Winkler B, HufnaglK, Spittler A et al. The role of Foxp3+ T cells in long-term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice. Allergy 2006; 61:173-80.
9. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108:S147-334.
10. Hufnagl K, Winkler B, Focke M et al. Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensitization in mice. J Allergy Clin Immunol 2005; 116:370-6.
11. Wiedermann U, Jahn-Schmid B, Bohle B et al. Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant bet v 1, the major birch pollen allergen, in a murine model of type I allergy. J Allergy Clin Immunol 1999; 103:1202-10.
12. Hufnagl K, Wagner B, Winkler B et al. Induction of mucosal tolerance with recombinant Hevb 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice. Clin Exp Immunol 2003; 133:170-6.
13. Kadl A, Huber J, Gruber F, Bochkov VN, Binder BR, Leitinger N. Analysis of inflammatory gene induction by oxidized phospho- lipids in vivo by quantitative real-time RT-PCR in comparison with effects of LPS. Vasc Pharmacol 2002; 38:219-27.
14. Cockcroft DW, Davis BE. Mechanisms of airway hyperrespon- siveness. J Allergy Clin Immunol 2006; 118:551-9.
15. Southam DS, Ellis R, Wattie J, Inman MD. Components of airway hyperresponsiveness and their associations with inflammation and remodeling in mice. J Allergy Clin Immunol 2007; 119:848-54.
16. Fasce L, Tosca MA, Olcese R, Milanese M, Erba D, Ciprandi G. The natural history of allergy: the development of new sensitizations in asthmatic children. Immunol Lett 2004; 93:45-50.
17. Antonicelli L, Micucci C, Voltolini S et al. Allergic rhinitis and asthma comorbidity: ARIA classification of rhinitis does not correlate with the prevalence of asthma. Clin Exp Allergy 2007; 37:954-60.
18. Hoyne GF, Askonas BA, Hetzel C, Thomas WR, Lamb JR. Regulation of house dust mite responses by intranasally administered peptide: transient activation of CD4+ T cells precedes the development of tolerance in vivo. Int Immunol 1996; 8:335-42.
19. Astori M, von Garnier C, Kettner A, Dufour N, Corradin G, Spertini F. Inducing tolerance by intranasal administration of long peptides in naive and primed CBA/J mice. J Immunol 2000; 165:3497-505.
20. Hall G, Houghton CG, Rahbek JU, Lamb JR, Jarman ER. Suppression of allergen reactive Th2 mediated responses and pulmonary eosinophilia by intranasal administration of an immunodomi- nant peptide is linked to IL-10 production. Vaccine 2003; 21:549-61.
21. Marazuela EG, Rodriguez R, Fernández-Garcia H, Garcia MS, Villalba M, Batanero E. Intranasal immunization with a dominant T-cell epitope peptide of a major allergen of olive pollen prevents mice from sensitization to the whole allergen. Mol Immunol 2008; 45:438-45.
22. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11 :S45-53.
23. Takabayashi K, Libet L, Chisholm D, Zubeldia J, Horner AA. Intranasal immunotherapy is more effective than intradermal immunotherapy for the induction of airway allergen tolerance in Th2-sensitized mice. J Immunol 2003; 170:3898-905.
24. Keller AC, Mucida D, Gomes E et al. Hierarchical suppression of asthma-like responses by mucosal tolerance. J Allergy Clin Immunol 2006; 117:283-90.
25. Francis JN, Durham SR. Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Curr Opin Allergy Clin Immunol 2004; 4:543-8.
26. Wild C, Wallner M, Hufnagl K et al. A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi-sensitivities. Allergy 2007; 62:33-41.
27. Akdis M, Verhagen J, Taylor A et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004; 199:1567-75.
28. - regulatory T cells. J Immunol 2006; 177:7634-44.
29. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100:655-69.
30. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997; 89:587-96.
31. Carson WF IV, Guernsey LA, Singh A, Vella AT, Schramm CM, Thrall RS. Accumulation of regulatory T cells in local draining lymph nodes of the lung correlates with spontaneous resolution of chronic asthma in a murine model. Int Arch Allergy Immunol 2007; 145:231-43.
32. + regulatory cells. J Immunol 2007; 179:7050-8.
33. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001; 2:725-31.
34. Akbari O, Freeman GJ, Meyer EH et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med 2002; 8:1024-32.